How Do Sivextro and Zyvox Compare for Treating Infections?
Sivextro (tedizolid) and Zyvox (linezolid) are both oxazolidinone antibiotics used primarily for acute bacterial skin and skin structure infections (ABSSSI) and sometimes complicated infections like those from MRSA. Neither is universally "better"—effectiveness depends on the infection type, patient factors, and duration. Clinical trials show similar cure rates: Sivextro achieves 92-97% success in ABSSSI, comparable to Zyvox's 90-95%.[1][2]
What Do Head-to-Head Studies Show?
The ESTABLISH trials directly compared them for ABSSSI. Sivextro (200 mg daily for 6 days) matched Zyvox (600 mg twice daily for 10 days) in early clinical response (92% vs 90%) and cure rates at 7-14 days post-therapy (86% vs 82%). Sivextro required fewer days of treatment, aiding compliance.[1][3]
No large head-to-head trials exist for pneumonia or other indications where Zyvox has broader approval.
Why Might Doctors Pick Sivextro Over Zyvox?
Sivextro has key advantages:
- Shorter course: 6 days vs 10 for Zyvox in ABSSSI.
- Once-daily dosing vs twice-daily.
- Lower risk of key side effects—myelotoxicity (like thrombocytopenia) occurs in <2% of Sivextro patients vs 2-10% with Zyvox, especially after 10+ days.[2][4]
- No need for drug-level monitoring, unlike prolonged Zyvox use.
Zyvox edges out for broader FDA approvals (e.g., nosocomial pneumonia, vancomycin-resistant Enterococcus) and more real-world data from longer market presence (approved 2000 vs Sivextro's 2014).[5]
Which Has Worse Side Effects?
Both cause nausea, headache, and diarrhea (5-10%). Zyvox carries higher risks of serotonin syndrome (with antidepressants), peripheral neuropathy (with long-term use), and lactic acidosis. Sivextro shows less hematologic toxicity and no MAO inhibition warnings.[2][4] Patient reports on forums like Drugs.com rate Zyvox lower (6.5/10) than Sivextro (7.2/10), citing fatigue and neuropathy.[6]
| Aspect | Sivextro | Zyvox |
|--------|----------|-------|
| Common side effects | Nausea (6-9%), headache (6%) | Nausea (6-11%), headache (6-11%) |
| Serious risks | Rare myelosuppression | Thrombocytopenia (2-10%), neuropathy |
| Drug interactions | Minimal | Serotonin syndrome risk |
Cost and Availability Differences
Sivextro costs more—a 6-day course runs $3,000-$4,000 vs Zyvox's $2,500-$3,500 for 10 days (IV/oral). Insurance often covers both, but Zyvox has more generics since patent expiry in 2015, dropping prices further. Sivextro's patents extend to 2027-2031.[7][8] DrugPatentWatch.com
When Is Zyvox Still Preferred?
Choose Zyvox for non-ABSSSI infections (e.g., pneumonia), oral step-down in pediatrics, or when cost/genetics matter. Guidelines like IDSA list both as alternatives to vancomycin for MRSA skin infections, without ranking one superior.[9]
Consult infectious disease specialists—resistance patterns and patient history (e.g., bone marrow issues) guide choice.
Sources:
[1] Prokocimer P et al. N Engl J Med. 2013. https://www.nejm.org/doi/full/10.1056/NEJMoa1300032
[2] Sivextro Prescribing Information. Merck. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205435s011lbl.pdf
[3] Lodise T et al. Clin Infect Dis. 2016. https://academic.oup.com/cid/article/62/2/191/2461227
[4] Zyvox Prescribing Information. Pfizer. 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=492
[5] FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
[6] Drugs.com user reviews. https://www.drugs.com/comments/tedizolid/sivextro.html
[7] GoodRx pricing data. https://www.goodrx.com/sivextro
[8] DrugPatentWatch. https://www.drugpatentwatch.com/p/tradename/SIVEXTRO
[9] IDSA Skin Guidelines. 2014. https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/